Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) EBITDA: 2009-2024

Historic EBITDA for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to -$21.5 million.

  • Lineage Cell Therapeutics' EBITDA rose 1.41% to -$3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$35.2 million, marking a year-over-year decrease of 54.78%. This contributed to the annual value of -$21.5 million for FY2024, which is 13.16% up from last year.
  • According to the latest figures from FY2024, Lineage Cell Therapeutics' EBITDA is -$21.5 million, which was up 13.16% from -$24.7 million recorded in FY2023.
  • In the past 5 years, Lineage Cell Therapeutics' EBITDA registered a high of -$21.5 million during FY2024, and its lowest value of -$49.2 million during FY2021.
  • Moreover, its 3-year median value for EBITDA was -$22.5 million (2022), whereas its average is -$22.9 million.
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 86.07% in 2021, then soared by 54.24% in 2022.
  • Yearly analysis of 5 years shows Lineage Cell Therapeutics' EBITDA stood at -$26.4 million in 2020, then crashed by 86.07% to -$49.2 million in 2021, then soared by 54.24% to -$22.5 million in 2022, then declined by 9.83% to -$24.7 million in 2023, then increased by 13.16% to -$21.5 million in 2024.